Vimarsana
Biggest News Aggregation in the World

Page 2 - Collective Coordinates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Collective Coordinates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Collective Coordinates Today - Breaking & Trending Today

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio - Vimarsana News

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology comp...

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference - Vimarsana News

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024. Presentation Details: Presen

Source: yahoo.com
ProMIS Neurosciences (TSE:PMN) Stock Price Down 3.8% - Vimarsana News

ProMIS Neurosciences (TSE:PMN) Stock Price Down 3.8%

ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) shares traded down 3.8% during mid-day trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. 19,701 shares changed hands during trading, an increase of 492% from the average session volume of 3,327 shares. The stock had previously closed at C$6.24. […]

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease - Vimarsana News

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology compan...

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights - Vimarsana News

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the...